<DOC>
	<DOCNO>NCT01699685</DOCNO>
	<brief_summary>The study purpose evaluate effect QAB149 - NVA237 vs. QAB149 static lung hyperinflation .</brief_summary>
	<brief_title>Swiss studY Treatment COPD Patients With Free combiNation indacatERol GlYcopyrroniumbromide .</brief_title>
	<detailed_description>This multicenter , randomize , double-blinded , single-dose , cross-over , placebo-controlled study . The primary endpoint choose demonstrate superiority single-dose combined inhalation vs. mono inhalation regard Inspiratory Capacity ( IC ) peak value . A total 78 patient randomized complete two visit two single dos treatment . Patients randomize cross-over manner . Treatment visit separate study medication wash-out period.Treatments administer blinded fashion . The patient male female patient , ≥40 year age , document diagnosis moderate severe COPD accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criterion &gt; 10-pack year history smoking , FEV1 &lt; 80 % ≥30 % predict normal value .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Inclusion criterion : Male female patient , ≥40 year age , document diagnosis moderate severe COPD accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criteria &gt; 10pack year history smoking FEV1 &lt; 80 % ≥30 % predict normal value sign informed consent form prior initiation studyrelated procedure Exclusion criterion : No COPD exacerbation within 6 week prior dose No concomitant lung disease asthma Nno requirement long term oxygen treatment history lung reduction surgery No medical condition would interfere performance spirometry No medical condition opinion investigator may cause patient unsuitable completion study place patient potential risk form study e.g . uncontrolled hypertension unstable ischemic heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Moderate severe COPD patient include</keyword>
	<keyword>NVA</keyword>
	<keyword>QAB</keyword>
</DOC>